tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARQT Stock Latest News

Arcutis Buy Rating: Zoryve’s Strengthened Pediatric Data and Undervalued Long-Term Revenue Potential
RatingsArcutis Buy Rating: Zoryve’s Strengthened Pediatric Data and Undervalued Long-Term Revenue Potential
10d ago
ARQT
Arcutis Biotherapeutics announces results for Phase 2 trial of Zoryve
PremiumThe Fly
Arcutis Biotherapeutics announces results for Phase 2 trial of Zoryve
11d ago
ARQT
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa
PremiumThe Fly
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa
18d ago
ARQT
Arcutis announces results of survey on inflammatory skin conditions
PremiumThe Fly
Arcutis announces results of survey on inflammatory skin conditions
23d ago
ARQT
Buy Rating on Arcutis Biotherapeutics Driven by Zoryve Commercial Momentum, Pipeline Upside, and Favorable Risk‑Reward Valuation
PremiumRatings
Buy Rating on Arcutis Biotherapeutics Driven by Zoryve Commercial Momentum, Pipeline Upside, and Favorable Risk‑Reward Valuation
1M ago
ARQT
Arcutis Biotherapeutics: Strengthening Zoryve Franchise, Approaching Profitability, and Multiple 2026+ Pipeline Catalysts Support Buy Rating
PremiumRatingsArcutis Biotherapeutics: Strengthening Zoryve Franchise, Approaching Profitability, and Multiple 2026+ Pipeline Catalysts Support Buy Rating
1M ago
ARQT
Arcutis Biotherapeutics sees FY26 ZORYVE revenue $455M-$470M
Premium
The Fly
Arcutis Biotherapeutics sees FY26 ZORYVE revenue $455M-$470M
1M ago
ARQT
Sustained Zoryve Prescription Momentum and Broad Dermatology Portfolio Underpin Buy Rating and $37 Target on Arcutis Biotherapeutics
Premium
Ratings
Sustained Zoryve Prescription Momentum and Broad Dermatology Portfolio Underpin Buy Rating and $37 Target on Arcutis Biotherapeutics
2M ago
ARQT
Arcutis Biotherapeutics Appoints Amit Munshi as New Director
PremiumCompany Announcements
Arcutis Biotherapeutics Appoints Amit Munshi as New Director
2M ago
8K
ARQT
Netflix target cut, Five Below target raised: Wall Street’s top analyst calls
PremiumThe Fly
Netflix target cut, Five Below target raised: Wall Street’s top analyst calls
3M ago
DE
ANF
Arcutis Biotherapeutics price target raised to $37 from $32 at Mizuho
PremiumThe Fly
Arcutis Biotherapeutics price target raised to $37 from $32 at Mizuho
3M ago
ARQT
Arcutis Biotherapeutics announces FDA acceptance of sNDA for ZORYVE
PremiumThe Fly
Arcutis Biotherapeutics announces FDA acceptance of sNDA for ZORYVE
3M ago
ARQT
Arcutis Biotherapeutics completes enrollment in INTEGUMENT-INFANT Phase 2 study
PremiumThe FlyArcutis Biotherapeutics completes enrollment in INTEGUMENT-INFANT Phase 2 study
3M ago
ARQT
Arcutis Biotherapeutics announces data from Phase 2 study of ZORYVE published
Premium
The Fly
Arcutis Biotherapeutics announces data from Phase 2 study of ZORYVE published
3M ago
ARQT
Arcutis partners with Tori Spelling, Stella McDermott for campaign
Premium
The Fly
Arcutis partners with Tori Spelling, Stella McDermott for campaign
4M ago
ARQT
Arcutis Biotherapeutics announces commercial launch of ZORYVE cream
PremiumThe Fly
Arcutis Biotherapeutics announces commercial launch of ZORYVE cream
4M ago
ARQT
Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs
PremiumThe Fly
Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs
4M ago
ARQT
Arcutis Biotherapeutics price target raised to $32 from $26 at Mizuho
PremiumThe Fly
Arcutis Biotherapeutics price target raised to $32 from $26 at Mizuho
4M ago
ARQT
Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright
PremiumThe Fly
Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright
4M ago
ARQT
Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
PremiumCompany AnnouncementsArcutis Biotherapeutics Reports Strong Q3 Earnings Call
4M ago
ARQT
Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating
Premium
Ratings
Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating
4M ago
ARQT
Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat
Premium
The Fly
Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat
4M ago
W
ARE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >